Skip to main content
. 2016 Nov 29;7(52):87431–87448. doi: 10.18632/oncotarget.13704

Figure 8. The activation of MAPK/ERK pathway contributes to cell proliferation in Sema3E-overexpressing MiaPaCa-2 cells.

Figure 8

A. Immunoblot analysis of Mia-S3E and Panc48-S3E cells and their respective controls shows that phosphorylated-ERK (pERK) levels were higher in Mia-S3E cells compared to Mia-VCtrl, while pERK levels in Panc48 cells remained the same regardless of Sema3E overexpression. B. Cell cycle analysis upon treatment of MiaPaCa-2 cells with MEK inhibitor trametinib shows that trametinib inhibited cell proliferation to a greater extent in Mia-S3E cells compared to Mia-VCtrl cells. This is reflected by the higher number of cells in G1 phase in Mia-S3E cells compared to Mia-VCtrl upon addition of trametinib, as well as fewer cells in both S phase and G2/M phase in Mia-S3E cells compared to Mia-VCtrl upon addition of trametinib (Student's t-test, **p<0.01, ***p<0.001). All data are represented as mean ± S.E.M, and are representative of at least 3 independent experiments.